New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Lung Cancer

• Publication date

  1995-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0169-5002(10)80007-8PMID 7551951
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunotherapy for Lung Cancer

  2015cited by this paper
• Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer

  2004cited by this paper
• Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer

  2004cited by this paper
• Saturday 28 November 1981 DIETARY VITAMIN A AND RISK OF CANCER IN THE WESTERN ELECTRIC STUDY

  2003cited by this paper
• Phase II trial of all-trans retinoic acid in metastatic non-small cell lung cancer.

  1996cited by this paper
• Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. 'Groupe Français de Pneumo-Cancérologie'.

  1996cited by this paper
• Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.

  1995cited by this paper
• A phase II trial of carboplatin (CA) and vindesine (V) in advanced adenocarcinoma of the lung

  1994cited by this paper
• Inhibition of proliferation by L-myc antisense DNA for the translational initiation site in human small cell lung cancer.

  1994cited by this paper
• Effect of gemcitabine on renal functions in non-small cell lung cancer (NSCLC)

  1994cited by this paper
• Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.

  1994cited by this paper
• Phase II Trial of 13-cis-Retinoic Acid Plus Interferon α in Non-Small-Cell Lung CancerFor the National Cancer Instit ute of Canada Clinical Trials Group

  1994cited by this paper
• Phase II study of cisplatin (CDDP), Ifosfamide (IFX) and vinorelbine (VNR) in stage IIIB-IV NSCLC

  1994cited by this paper
• Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.

  1994cited by this paper
• Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.

  1994cited by this paper
• Neoadjuvant chemotherapy for non small cell lung carcinoma-stage III A-B

  1994cited by this paper
• Platinum-based chemotherapy for inoperable non-small cell lung cancer: a real therapeutic progress?

  1994cited by this paper
• Cisplatin/ifosfamide/vinblastine (VIP) vs, cisplatin/ifosfamide etoposide (VIR-16) in non-small cell lung cancer (NSCLC). A prospective randomized phase III study

  1994cited by this paper
• Preoperative radiotherapy for non small cell lung carcinoma (NSCLC)

  1994cited by this paper
• A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

  1994cited by this paper
• News from the editor

  1994cited by this paper
• Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.

  1994cited by this paper
• Treatment characteristics in patients surviving five to 18+ years. An analysis of 1714 consecutive patients

  1994cited by this paper
• Enhancement of C.E.V combination (cisplatin, epirubicin, vindesine) in advanced NSCLC by lonidamine. A phase II randomized trial

  1994cited by this paper
• A phase II trial with oral etoposide (VP-16) and weekly cisplatin (CDDP) in non small cell lung cancer (NSCLC)

  1994cited by this paper
• Cisplatin-vinorelbine (DDP+VBN) association chemotherapy in the treatment of locally advanced N.S.C.L.C.

  1994cited by this paper
• Prognostic significance of histologic complete remission in neoadjuvant trials in stage III non-small cell lung cancer (NSCLC)

  1994cited by this paper
• Combination chemotherapy with mitomycin, vinblastine and cisplatinum for advanced non small cell lung cancer (NSCLC)

  1994cited by this paper
• Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.

  1994cited by this paper
• Phase II study with paclitaxel in advanced inoperable non-small cell lung cancer (NSCLC)—The European experience

  1994cited by this paper
• Ifosfamide (IFO)+vinorelbine (VRL) as treatment for advanced, non operable non small cell lung cancer (NSCLC)

  1994cited by this paper
• Phase II study of topotecan in metastatic non-small-cell lung cancer.

  1994cited by this paper
• Radiation sensitization of human lung cancer cells

  1994cited by this paper
• Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.

  1994cited by this paper
• Second-line with vinorelbine in the weekly monochemotherapy for the treatment of advanced non small cell lung cancer (NSCLC)

  1994cited by this paper
• Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.

  1994cited by this paper
• CDDP (P), 5FU (F), leucovorin (L) and VP16 (PFL-VP16) in advanced non small cell lung cancer (NSCLC)

  1994cited by this paper
• Recombinant human interleukin 4 (IL-4) sch 39400 in non-small cell lung cancer (NSCLC): Results of a phase II investigation

  1994cited by this paper
• Phase II trial of 13-cis-retinoic acid plus interferon alpha in non-small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.

  1994cited by this paper
• Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results.

  1993cited by this paper
• Polychemotherapy in advanced non small cell lung cancer: a meta-analysis.

  1993cited by this paper
• Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial Group.

  1993cited by this paper
• Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.

  1993cited by this paper
• Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer.

  1993cited by this paper
• Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

  1993influential reference
• Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients.

  1993cited by this paper
• Pharmacokinetic re-evaluation and phase I study of high dose epirubicin in advanced non-small cell lung cancer.

  1993cited by this paper
• Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor.

  1993cited by this paper
• Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.

  1993cited by this paper
• Adjuvant treatment of stage I lung cancer with high-dose vitamin A.

  1993cited by this paper
• Phase II study of 13-cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer.

  1993cited by this paper
• Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor.

  1993cited by this paper
• A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small-cell lung cancer (NSCLC).

  1992cited by this paper
• A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.

  1992cited by this paper
• p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking.

  1992cited by this paper
• 13-cis-Retinoic Acid Plus Interferon α -2a: Highly Active Systemic Theraphy for Squamous Cell Carcinoma of the Cervix

  1992cited by this paper
• Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.

  1992cited by this paper
• Clinical significance of ras oncogene activation in human lung cancer.

  1992cited by this paper
• 13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix.

  1992cited by this paper
• Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.

  1992cited by this paper
• Autocrine growth stimulation by transforming growth factor-alpha in human non-small cell lung cancer.

  1992cited by this paper
• 13-cis-Retinoic Acid and Interferon α -2a: Effective Combination. Therapy for Advanced Squamous Cell Carcinoma of the Skin

  1992cited by this paper
• Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

  1992cited by this paper
• Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma.

  1992cited by this paper
• Autocrine growth stimulation by transforming growth factor-α in human non-small cell lung cancer

  1992cited by this paper
• CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer.

  1992cited by this paper
• Phase II study of high-dose epirubicin and etoposide in advanced non-small cell lung cancer.

  1992cited by this paper
• 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin.

  1992cited by this paper
• A phase II study of high dose epirubicin in unresectable non small cell lung cancer.

  1992cited by this paper
• Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions.

  1992cited by this paper
• Combination Chemotherapy (CT) and recombinant (r) $alpha; interferon (IFN): Final result of fonicap randomized study

  1991cited by this paper
• Activity of high-dose epirubicin in advanced non-small cell lung cancer.

  1991cited by this paper
• Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer

  1991cited by this paper
• A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

  1991cited by this paper
• A Phase II Study of Navelbine (Vinorelbine) in the Treatment of Non‐Small‐Cell Lung Cancer

  1991cited by this paper
• High frequency of retinoic acid receptor beta abnormalities in human lung cancer.

  1991cited by this paper
• [A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group].

  1991cited by this paper
• Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer.

  1991cited by this paper
• Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).

  1991cited by this paper
• Combination immunotherapy for non-small cell lung cancer. Results with interleukin-2 and tumor necrosis factor-alpha.

  1990cited by this paper
• Phase II study of high-dose epirubicin in non-small cell lung cancer.

  1990cited by this paper
• A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.

  1990cited by this paper
• Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

  1990cited by this paper
• A novel alteration in the epidermal growth factor receptor gene is frequently detected in human non-small cell lung cancer

  1990cited by this paper
• Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.

  1990cited by this paper
• TGF-β stimulation and inhibition of cell proliferation: New mechanistic insights

  1990cited by this paper
• Functional expression of specific subsets of enhancer binding proteins associated with the differentiation state of lung carcinomas

  1990cited by this paper
• Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.

  1990cited by this paper
• Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer

  1990cited by this paper
• TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights.

  1990cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.

  1989cited by this paper
• Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients

  1989cited by this paper
• Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.

  1988cited by this paper
• Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.

  1988cited by this paper
• The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. The Lung Cancer Study Group.

  1988cited by this paper
• Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer.

  1988cited by this paper
• Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung.

  1987cited by this paper
• Diet and lung cancer. A review of the epidemiologic evidence in humans.

  1987cited by this paper
• myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course.

  1987cited by this paper

• The Role of Oral Etoposide in Non-Small Cell Lung Cancer

  2012cites this paper
• The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysis

  2007cites this paper
• Trends in the aggressiveness of cancer care near the end of life.

  2004cites this paper
• Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial.

  2001cites this paper
• A Phase I Trial of Cisplatin Plus Decitabine, a New DNA-Hypomethylating Agent, in Patients with Advanced Solid Tumors and a Follow-Up Early Phase II Evaluation in Patients with Inoperable Non-Small Cell Lung Cancer

  2000cites this paper
• Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma

  2000cites this paper
• Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.

  1999cites this paper
• Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer

  1999cites this paper
• [Non-metastatic advanced non-small cell lung carcinoma: systemic high-dose brachytherapy following curative external radiotherapy].

  1999cites this paper
• Cancers bronchiques non à petites cellules localement évolués : curiethérapie de haut débit de dose complémentaire d'une radiothérapie externe à visée curative

  1999cites this paper
• Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.

  1999cites this paper
• Chemotherapy for advanced (stage IIIB and stage IV) non‐small cell lung cancer: The Hong Kong perspective

  1998cites this paper
• Expression of lung-resistance protein gene is not associated with platinum drug exposure in lung cancer.

  1998cites this paper
• Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.

  1997cites this paper
• UFT plus cisplatin in advanced non-small-cell lung cancer: interim analysis of 67 patients.

  1997cites this paper
• Management strategies for recurrent non-small cell lung cancer.

  1997cites this paper
• Paclitaxel as a radiosensitiser: a proposed schedule of administration based on in vitro data and pharmacokinetic calculations.

  1997cites this paper
• Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study.

  1997cites this paper
• Non-small cell lung cancer: novel treatment strategies.

  1997cites this paper
• Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients.

  1996cites this paper
• Non-small cell lung cancer: an overview of diagnosis, staging, and treatment.

  1996cites this paper
• Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). The Japan Vinorelbine Lung Cancer Cooperative Study Group.

  1996cites this paper